Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:50 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Abituzumab in SSc-ILD
NCT02745145 · EMD Serono Research & Development Institute, Inc. · PHASE2 · terminated · last registry update 2019-06-18 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Difficulties experienced in identifying participants who meet the eligibility criteria of the trial.” | – | Registry record, EMD Serono Research & Development Institute, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ITGB1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-04-17Results posted on the registry: Dana-Farber Cancer Institute, Natalizumab + Methylprednisolone (NCT02176031)
- 2020-03-18Also stopped (withdrawn): SFJ Pharmaceuticals X, LTD., abituzumab + Placebo + Cetuximab + FOLFIRI (NCT03688230)
- 2019-10-04Phase 3 first posted: Polpharma Biologics S.A., Intravenous (IV) infusions (NCT04115488)
- 2019-09-27Also stopped (terminated): Biogen, Daclizumab (NCT02881567)
- 2019-09-24Results posted on the registry: Biogen, Daclizumab (NCT02881567)
- 2019-08-07Phase 3 first posted: National Institute of Allergy and Infectious Diseases (NIAID), Best Available Therapy (BAT) (NCT04047628)
- 2019-01-08Results posted on the registry: Biogen, natalizumab + Placebo (NCT02730455)
- 2018-10-01Phase 3 first posted: Biogen, Natalizumab + Natalizumab (NCT03689972)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision